Aarti Pharmalabs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 10:01 am

Competitors of Aarti Pharmalabs Ltd

All Competitor Stocks of Aarti Pharmalabs Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:50 am

Below is a detailed analysis of the quarterly data for Aarti Pharmalabs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 386.00 Cr.. The value appears to be declining and may need further review. It has decreased from 564.00 Cr. (Mar 2025) to 386.00 Cr., marking a decrease of 178.00 Cr..
• For Expenses, as of Jun 2025, the value is 293.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 418.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 125.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 146.00 Cr. (Mar 2025) to 93.00 Cr., marking a decrease of 53.00 Cr..
• For OPM %, as of Jun 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 24.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
• For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 65.00 Cr.. The value appears to be declining and may need further review. It has decreased from 115.00 Cr. (Mar 2025) to 65.00 Cr., marking a decrease of 50.00 Cr..
• For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 24.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 50.00 Cr.. The value appears to be declining and may need further review. It has decreased from 88.00 Cr. (Mar 2025) to 50.00 Cr., marking a decrease of 38.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 5.46. The value appears to be declining and may need further review. It has decreased from 9.75 (Mar 2025) to 5.46, marking a decrease of 4.29.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:06 am

Growth

Last Updated: September 5, 2025, 2:01 pm

Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Aarti Pharmalabs Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
• For Diluted EPS (Rs.), as of Mar 25, the value is 30.04. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.04, marking an increase of 6.11.
• For Cash EPS (Rs.), as of Mar 25, the value is 39.64. This value is within the healthy range. It has increased from 32.01 (Mar 24) to 39.64, marking an increase of 7.63.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 219.55. It has increased from 193.88 (Mar 24) to 219.55, marking an increase of 25.67.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 233.36. It has increased from 204.42 (Mar 24) to 233.36, marking an increase of 28.94.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 52.35. This value is within the healthy range. It has increased from 43.14 (Mar 24) to 52.35, marking an increase of 9.21.
• For PBIT / Share (Rs.), as of Mar 25, the value is 42.76. This value is within the healthy range. It has increased from 35.06 (Mar 24) to 42.76, marking an increase of 7.70.
• For PBT / Share (Rs.), as of Mar 25, the value is 39.80. This value is within the healthy range. It has increased from 33.16 (Mar 24) to 39.80, marking an increase of 6.64.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 30.06. This value is within the healthy range. It has increased from 23.93 (Mar 24) to 30.06, marking an increase of 6.13.
• For PBDIT Margin (%), as of Mar 25, the value is 22.43. This value is within the healthy range. It has increased from 21.10 (Mar 24) to 22.43, marking an increase of 1.33.
• For PBIT Margin (%), as of Mar 25, the value is 18.32. This value is within the healthy range. It has increased from 17.14 (Mar 24) to 18.32, marking an increase of 1.18.
• For PBT Margin (%), as of Mar 25, the value is 17.05. This value is within the healthy range. It has increased from 16.21 (Mar 24) to 17.05, marking an increase of 0.84.
• For Net Profit Margin (%), as of Mar 25, the value is 12.87. This value exceeds the healthy maximum of 10. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.87. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 12.87, marking an increase of 1.17.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.68. This value is below the healthy minimum of 15. It has increased from 12.34 (Mar 24) to 13.68, marking an increase of 1.34.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.23. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 17.23, marking an increase of 0.40.
• For Return On Assets (%), as of Mar 25, the value is 9.37. This value is within the healthy range. It has increased from 8.40 (Mar 24) to 9.37, marking an increase of 0.97.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.15 (Mar 24) to 0.19, marking an increase of 0.04.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has increased from 0.76 (Mar 24) to 0.77, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.01, marking an increase of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 1.12. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.12, marking an increase of 0.11.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.44, marking an increase of 2.06.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.64. This value is below the healthy minimum of 20. It has increased from 8.35 (Mar 24) to 11.64, marking an increase of 3.29.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 6.24 (Mar 24) to 8.82, marking an increase of 2.58.
• For Earning Retention Ratio (%), as of Mar 25, the value is 88.36. This value exceeds the healthy maximum of 70. It has decreased from 91.65 (Mar 24) to 88.36, marking a decrease of 3.29.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 93.76 (Mar 24) to 91.18, marking a decrease of 2.58.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 17.64. This value is within the healthy range. It has decreased from 22.71 (Mar 24) to 17.64, marking a decrease of 5.07.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.13. This value is within the healthy range. It has decreased from 13.60 (Mar 24) to 11.13, marking a decrease of 2.47.
• For Enterprise Value (Cr.), as of Mar 25, the value is 7,172.16. It has increased from 4,182.27 (Mar 24) to 7,172.16, marking an increase of 2,989.89.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.26 (Mar 24) to 3.39, marking an increase of 1.13.
• For EV / EBITDA (X), as of Mar 25, the value is 15.12. This value exceeds the healthy maximum of 15. It has increased from 10.70 (Mar 24) to 15.12, marking an increase of 4.42.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
• For Retention Ratios (%), as of Mar 25, the value is 88.35. This value exceeds the healthy maximum of 70. It has decreased from 91.64 (Mar 24) to 88.35, marking a decrease of 3.29.
• For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has increased from 2.24 (Mar 24) to 3.41, marking an increase of 1.17.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.21, marking an increase of 1.08.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness